Daiichi Sankyo Nordics ApS: Financial statements 2020
CVR: 39371049
Source: annual report 2020, Danish Business Authority
01/04/2019 – 31/03/2020
Daiichi Sankyo Nordics ApS (CVR 39371049) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK 20,610,270 and a net result of DKK 1,187,436 compared with DKK 253,181 the year before. That is an increase of 616.4% compared with the year before. Equity in the 2020 report amounted to DKK 2,490,617. The solvency ratio was 24.9%. The company had 16 employees in the financial year.
- Gross Profit
- DKK 20,610,270
- Profit/Loss
- DKK 1,187,436
- Equity
- DKK 2,490,617
- Total Assets
- DKK 9,999,516
- Employees
- 16
Official annual report
How creditworthy is Daiichi Sankyo Nordics ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
As of August 1, 2020, Åke Magnus Gisel has joined the board of directors of Daiichi Sankyo Nordics ApS.
As of August 1, 2020, Åke Magnus Gisel is registered as director of Daiichi Sankyo Nordics ApS.
As of July 31, 2020, Nicola Torosantucci has left the board of directors of Daiichi Sankyo Nordics ApS.
As of July 31, 2020, Nicola Torosantucci has stepped down as director of Daiichi Sankyo Nordics ApS.
As of June 1, 2020, Nicola Torosantucci has joined the board of directors of Daiichi Sankyo Nordics ApS.
As of June 1, 2020, Nicola Torosantucci is registered as director of Daiichi Sankyo Nordics ApS.
As of May 31, 2020, Patrik Josef Mag. Grandits has left the board of directors of Daiichi Sankyo Nordics ApS.
As of May 31, 2020, Patrik Josef Grandits has stepped down as adm. dir. of Daiichi Sankyo Nordics ApS.
About Daiichi Sankyo Nordics ApS
Daiichi Sankyo Nordics ApS is a Danish company of the type Anpartsselskab based in København S, founded in 2018. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named Daiichi Sankyo Oncology Nordics ApS. The management consists of Christophe Tiberghien. The board consists of Christophe Tiberghien, Jacob Wessel-Tolvig and Karin Margaretha Heisterberg. The company is owned by Daiichi Sankyo Oncology Europe GmbH. The company has 32 employees (2026). In 2026, the company reported a gross profit of DKK 83,558,930 and a net result of DKK 17,269,490 compared with DKK 9,020,707 the year before. Equity in the 2026 report amounted to DKK 40,346,412.